A coating composition for application to an expandable medical device including a polymeric compound including a central portion and two end portions wherein either the central portion is hydrophobic and the end portions are hydrophilic or the central portion is hydrophilic and the end portions are hydrophobic; at least one active agent wherein at least one active agent is hydrophobic when the central portion of the polymeric compound is hydrophobic and at least one active agent is hydrophilic when the central portion of the polymeric compound is hydrophilic; and a solvent; when in use the at least one active agent is encapsulated by the polymeric compound; and at least one active agent is a vasodilator and/or an anti-platelet agent. The invention extends to a coating composition system comprising the coating composition.
A61L 29/16 - Biologically active materials, e.g. therapeutic substances
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A coating composition for application to an expandable medical device comprising a polymeric compound comprising a central portion and two end portions wherein either the central portion is hydrophobic and the end portions are hydrophilic or the central portion is hydrophilic and the end portions are hydrophobic; at least one active agent wherein at least one active agent is hydrophobic when the central portion of the polymeric compound is hydrophobic and at least one active agent is hydrophilic when the central portion of the polymeric compound is hydrophilic; and a solvent; wherein, in use the at least one active agent is encapsulated by the polymeric compound; and wherein at least one active agent is a vasodilator and/or an anti-platelet agent. The invention extends to a coating composition system comprising the coating composition.
A coating composition for application to an expandable medical device comprising a polymeric compound comprising a central portion and two end portions wherein either the central portion is hydrophobic and the end portions are hydrophilic or the central portion is hydrophilic and the end portions are hydrophobic; at least one active agent wherein at least one active agent is hydrophobic when the central portion of the polymeric compound is hydrophobic and at least one active agent is hydrophilic when the central portion of the polymeric compound is hydrophilic; and a solvent; wherein, in use the at least one active agent is encapsulated by the polymeric compound; and wherein at least one active agent is a vasodilator and/or an anti-platelet agent. The invention extends to a coating composition system comprising the coating composition.
The invention relates to a two part hardenable composition comprising a solid first part and a storage stable liquid second part. The parts are operable to form a resorbable and injectable bone cement which hardens to a solid mass upon mixing of the parts together. The solid first part comprises a filler and/or polymer particles, wherein each of the filler and the polymer particles, when present, have an average particle size of up to 200 µm and wherein the polymer particles, when present, have a weight-average molecular weight (Mw) of at least 10,000 Da; and 0.01 to 15 wt% of an initiator based on the total weight of the solid first part. The storage stable liquid second part comprises a monomer component, wherein the monomer component is operable to undergo free radical polymerisation in the presence of the initiator to form a polymer upon mixing of the parts together; and 0.5 to 50 wt% of a crosslinker material based on the total weight of the storage stable liquid part. Each of the polymer particles, when present, and the polymer formed from the free radical polymerisation of the monomer component are resorbable. The invention extends to a two part hardenable composition for use in the treatment of human or animal bone and a kit of parts comprising the two part hardenable composition and a syringe or caulking gun.
A tubular stent has first and second ends and a longitudinal axis therebetween. The tubular stent is formed from a network of struts which defines a cylindrical surface about the longitudinal axis, the struts delineating a plurality of cells within the network, there being rows of cells parallel to the longitudinal axis. At least one cell in each row is a nodal cell. There is an increase in the maximum length parallel to the longitudinal axis of cells from the nodal cell to a first distal cell in the row that is closer to the first or second end of the tubular stent. There is a second distal cell in the row which has a different maximum length parallel to the longitudinal axis from the nodal cell and the first distal cell. The network of struts comprises a plurality of circumferential rings. Each ring extends perpendicularly to the longitudinal axis and the rings are located adjacent to each other parallel to the longitudinal axis to define the cylindrical surface. The circumferential rings are of a wave form. Each circumferential ring has an amplitude parallel to the longitudinal axis, such that each wave form comprises a plurality of peaks which extend towards the axial center of the tubular stent and a plurality of troughs which extend away from the axial center of the tubular stent.
A61F 2/915 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
A61F 2/86 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure
6.
Method of producing a tube for use in the formation of a stent, and such tube
Bioresorbable polymeric tubes suitable for use in a stent have been produced by a using a die drawing technique, comprising: —deforming an orientable, thermoplastic polymer tubing (4) in the solid phase by drawing it over a mandrel (1) and/or through a die (3), where the mandrel (1) has a lead end and an exit end and the die (3) has an entry side and an exit side, wherein a drawing mechanism applies a drawing tension to the tubing (4) from the exit end of the mandrel (1) and/or the exit side of the die (3), said tension being insufficient to cause tensile failure of the tubing but sufficient to deform the tubing, thereby drawing the tubing over the mandrel (1) and/or through the die (3) in the solid phase to induce uniaxial or biaxial orientation of the polymer; and —collecting the deformed tubing from the exit end of the mandrel (1) and/or the exit side of the die (3).
B29C 55/24 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of tubes radial
B29C 55/22 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of tubes
A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
B29C 47/00 - Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor (extrusion blow-moulding B29C 49/04)
B29C 55/26 - Shaping by stretching, e.g. drawing through a dieApparatus therefor of tubes biaxial
A tubular stent (1) has first and second ends (2,3) and a longitudinal axis (4) therebetween. The tubular stent (1) is formed from a network of struts which defines a cylindrical surface about the longitudinal axis (4), the struts delineating a plurality of cells {23, 30, 31, 32, 33) within the network, there being rows of cells parallel to the longitudinal axis (4). At least one cell in each row is a nodal cell (23). There is an increase in the maximum length parallel to the longitudinal axis (4) of cells from the at least one nodal cell (23) to a first distal cell (30) in the row that is closer to the first or second end (2, 3) of the tubular stent (1). There is a second distal cell (31) in the row which has a different maximum length parallel to the longitudinal axis (4) from the nodal cell (23) and the first distal cell (30). The network of struts comprises a plurality of circumferential rings (6, 6′, 9, 9′, 13, 13′, 16, 16′, 17, 17′). Each ring (6, 6′, 9, 9′, 13, 13′, 16, 16′, 17, 17′) extends perpendicularly to the longitudinal axis (4) and the rings are located adjacent to each other parallel to the longitudinal axis (4) to define the cylindrical surface. The circumferential rings (6, 6′, 9, 9′, 13, 13′, 16, 16′, 17, 17′) are of a wave form. Each circumferential ring (6, 6′, 9, 9′, 13, 13′, 16, 16′, 17, 17′) has an amplitude parallel to the longitudinal axis (4), such that each wave form comprises a plurality of peaks (7, 10, 14, 18, 20) which extend towards the axial centre (5) of the tubular stent (1) and a plurality of troughs (8, 12, 29, 21, 36) which extend away from the axial centre (5) of the tubular stent (1).
A61F 2/86 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure
A61F 2/915 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
8.
METHOD OF PRODUCING A TUBE FOR USE IN THE FORMATION OF A STENT, AND SUCH TUBE
Bioresorbable polymeric tubes suitable for use in a stent have been produced by a using a die drawing technique, comprising: - deforming an orientable, thermoplastic polymer tubing (4) in the solid phase by drawing it over a mandrel (1) and/or through a die (3), where the mandrel (1) has a lead end and an exit end and the die (3) has an entry side and an exit side, wherein a drawing mechanism applies a drawing tension to the tubing (4) from the exit end of the mandrel (1) and/or the exit side of the die (3), said tension being insufficient to cause tensile failure of the tubing but sufficient to deform the tubing, thereby drawing the tubing over the mandrel (1) and/or through the die (3) in the solid phase to induce uniaxial or biaxial orientation of the polymer; and - collecting the deformed tubing from the exit end of the mandrel (1) and/or the exit side of the die (3).
A tubular stent (1) has first and second ends (2,3) and a longitudinal axis (4) therebetween. The tubular stent (1) is formed from a network of struts which defines a cylindrical surface about the longitudinal axis (4), the struts delineating a plurality of cells {23, 30, 31, 32, 33) within the network, there being rows of cells parallel to the longitudinal axis (4). At least one cell in each row is a nodal cell (23). There is an increase in the maximum length parallel to the longitudinal axis (4) of cells from the at (east one nodal cell (23) to a first distal cell (30) in the row that is closer to the first or second end (2, 3) of the tubular stent (1). There is a second distal cell (31) in the row which has a different maximum length parallel to the longitudinal axis (4) from the nodal cell (23) and the first distal cell (30). The network of struts comprises a plurality of circumferential rings (6, 6', 9, 9', 13, 13', 16, 16', 17, 17'). Each ring (6, 6', 9, 9', 13, 13', 16, 16', 17, 17') extends perpendicularly to the longitudinal axis (4) and the rings are located adjacent to each other parallel to the longitudinal axis (4) to define the cylindrical surface. The circumferential rings (6, 6', 9, 9', 13, 13', 16, 16', 17, 17') are of a wave form. Each circumferential ring (6, 6', 9, 9', 13, 13', 16, 16', 17, 17') has an amplitude parallel to the longitudinal axis (4), such that each wave form comprises a plurality of peaks (7, 10, 14, 18, 20) which extend towards the axial centre (5) of the tubular stent (1) and a plurality of troughs (8, 12, 29, 21, 36) which extend away from the axial centre (5) of the tubular stent (1).
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
11.
BIODEGRADABLE STENT COMPRISING AN ACID SCAVENGING AGENT
A biodegradable stent comprising a biodegradable material having dissolved therein an acid scavenging agent. The biodegradable material may be PLLA or PLGA. The acid scavenging agent may be also a pharmaceutical agent, for example an antiproliferative agent, coronary vasodilator agent and/or a bronchodilator. Preferably the acid scavenging agent is dipyridamole and/or mopidamol. The invention also provides a method of preparing a biodegradable material for use in the stent of the invention comprising: (i) preparing a formulation of the biodegradable material and the acid scavenging agent; (ii) heating the formulation to melt the biodegradable material and the acid scavenging agent so as to dissolve the agent in the material; and (iii) collecting and cooling the formulation of step (ii).
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical apparatus and instruments, in particular stents for use in cardiovascular surgery and parts and fittings thereof. Scientific and technological services; scientific research; design and development in the field of medical and surgical devices and apparatus; scientific and technical research in the field of arteries and veins.
